San Diego—The CD30-targeted antibody–drug conjugate brentuximab vedotin (BV) was far more active than current standard-of-care therapies for cutaneous T cell lymphoma (CTCL) in the Phase III ALCANZA trial.
The primary end point of objective response rate lasting at least four months (ORR4) was achieved by 56% of patients randomly assigned to BV and 13% of those randomly assigned to a physician’s choice of methotrexate or bexarotene (P<0.0001).